{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+vaccine", "query": { "intervention": "Placebo vaccine" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 982, "total_pages": 99, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+vaccine&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-21T11:30:37.487Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01352845", "title": "A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "rLP2086", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "18 Years to 25 Years" }, "enrollment_count": 3301, "start_date": "2013-05", "completion_date": "2015-02", "has_results": true, "last_update_posted_date": "2016-02-23", "last_synced_at": "2026-09-21T11:30:37.487Z", "location_count": 35, "location_summary": "Mobile, Alabama • Mesa, Arizona • Tempe, Arizona + 28 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01352845" }, { "nct_id": "NCT00065442", "title": "Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Sipuleucel-T", "type": "BIOLOGICAL" }, { "name": "APC-Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Dendreon", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 512, "start_date": "2003-07", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2010-09-06", "last_synced_at": "2026-09-21T11:30:37.487Z", "location_count": 65, "location_summary": "Laguna Hills, California • Loma Linda, California • Los Angeles, California + 49 more", "locations": [ { "city": "Laguna Hills", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00065442" }, { "nct_id": "NCT04722003", "title": "Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gonorrhoea" ], "interventions": [ { "name": "Meningococcal Group B Vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 52, "start_date": "2021-11-01", "completion_date": "2023-10-02", "has_results": true, "last_update_posted_date": "2024-11-05", "last_synced_at": "2026-09-21T11:30:37.487Z", "location_count": 1, "location_summary": "Decatur, Georgia", "locations": [ { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04722003" }, { "nct_id": "NCT02822105", "title": "Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Flu" ], "interventions": [ { "name": "the H3N2 M2SR monovalent influenza vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "FluGen Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 96, "start_date": "2016-06", "completion_date": "2017-11", "has_results": false, "last_update_posted_date": "2020-08-10", "last_synced_at": "2026-09-21T11:30:37.487Z", "location_count": 1, "location_summary": "Lenexa, Kansas", "locations": [ { "city": "Lenexa", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02822105" }, { "nct_id": "NCT01254175", "title": "Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Parainfluenza Virus 3, Human" ], "interventions": [ { "name": "rHPIV3cp45 Vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Months", "maximum_age": "36 Months", "sex": "ALL", "summary": "6 Months to 36 Months" }, "enrollment_count": 28, "start_date": "2010-12", "completion_date": "2012-02", "has_results": false, "last_update_posted_date": "2014-12-03", "last_synced_at": "2026-09-21T11:30:37.487Z", "location_count": 7, "location_summary": "Long Beach, California • San Diego, California • Chicago, Illinois + 3 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01254175" }, { "nct_id": "NCT06702449", "title": "A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Urinary Tract Infections" ], "interventions": [ { "name": "Candidate UTI vaccine low dose formulation 1", "type": "COMBINATION_PRODUCT" }, { "name": "Candidate UTI vaccine low dose formulation 2", "type": "COMBINATION_PRODUCT" }, { "name": "Candidate UTI vaccine medium dose formulation 1", "type": "COMBINATION_PRODUCT" }, { "name": "Candidate UTI vaccine medium dose formulation 2", "type": "COMBINATION_PRODUCT" }, { "name": "Candidate UTI vaccine high dose formulation 1", "type": "COMBINATION_PRODUCT" }, { "name": "Candidate UTI vaccine high dose formulation 2", "type": "COMBINATION_PRODUCT" }, { "name": "Candidate UTI vaccine HTD formulation 2", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 448, "start_date": "2024-11-19", "completion_date": "2027-05-31", "has_results": false, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-09-21T11:30:37.487Z", "location_count": 6, "location_summary": "Lenexa, Kansas • Secaucus, New Jersey • Rochester, New York + 3 more", "locations": [ { "city": "Lenexa", "state": "Kansas" }, { "city": "Secaucus", "state": "New Jersey" }, { "city": "Rochester", "state": "New York" }, { "city": "Weatherford", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06702449" }, { "nct_id": "NCT06907511", "title": "Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pandemic Influenza Immunization", "Healthy Volunteers" ], "interventions": [ { "name": "Pandemic flu H5 HA mRNA SD2 vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 720, "start_date": "2025-04-17", "completion_date": "2026-12-01", "has_results": false, "last_update_posted_date": "2026-01-16", "last_synced_at": "2026-09-21T11:30:37.487Z", "location_count": 13, "location_summary": "La Mesa, California • DeLand, Florida • Lakeland, Florida + 10 more", "locations": [ { "city": "La Mesa", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Lakeland", "state": "Florida" }, { "city": "Largo", "state": "Florida" }, { "city": "Decatur", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06907511" }, { "nct_id": "NCT00925548", "title": "STRIDE - STimulating Immune Response In aDvanced brEast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Tecemotide (L-BLP25) and Hormonal Treatment", "type": "BIOLOGICAL" }, { "name": "Placebo of tecemotide (L-BLP25) and Hormonal Treatment", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "sodium chloride (NaCl)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "EMD Serono", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 16, "start_date": "2009-09", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2014-07-24", "last_synced_at": "2026-09-21T11:30:37.487Z", "location_count": 1, "location_summary": "Hickory, North Carolina", "locations": [ { "city": "Hickory", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00925548" }, { "nct_id": "NCT07425821", "title": "A Phase 1 Randomized, Observer-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Marburg Virus Disease" ], "interventions": [ { "name": "rVSV∆G-MARV-GP", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "International AIDS Vaccine Initiative", "sponsor_class": "NETWORK", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 112, "start_date": "2026-03-27", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-09-21T11:30:37.487Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Lenexa, Kansas", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Lenexa", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07425821" }, { "nct_id": "NCT06829238", "title": "Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Systemic Inflammation", "Immune Dysregulation", "Injection Drug Use", "HIV" ], "interventions": [ { "name": "Metformin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Jynneos", "type": "BIOLOGICAL" }, { "name": "Capvaxvie", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 100, "start_date": "2025-04-07", "completion_date": "2029-11-30", "has_results": false, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-09-21T11:30:37.487Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT06829238" } ] }